Therapeutic T-Cell Receptors Targeting KRAS G12D
OwnerMark Klinger, Soyoung Oh +5inventors
InventorsMark Klinger, Soyoung Oh, Sascha Rutz, Rena Whei-Ming Yang, Erik Yusko, Peter Ebert, Kate Halliwell Senger
Life of this patent
Estimating the term…
Abstract
Disclosed herein are therapeutic T cell receptors (TCRs) that bind to a KRAS G12D neoantigen, engineered cells expressing such TCRs, pharmaceutical compositions comprising such cells, and methods of treatment using such cells or pharmaceutical compositions.
Claims70
A recombinant T cell receptor (TCR) that binds to a Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D neoantigen comprising:
- a TCR-alpha chain comprising a TCR-alpha variable region;
- and
- a TCR-beta chain comprising a TCR-beta variable region;
- wherein the TCR-alpha variable region comprises the following:
- a CDR1 comprising the amino acid sequence SEQ ID NO:
- 7,
- a CDR2 comprising the amino acid sequence SEQ ID NO:
- 8, and
- a CDR3 comprising amino the acid sequence SEQ ID NO:
- 9;
- and
- wherein the TCR-beta variable region comprises the following:
- a CDR1 comprising the amino acid sequence SEQ ID NO:
- 3,
- a CDR2 comprising the amino acid sequence SEQ ID NO:
- 4, and
- a CDR3 comprising the amino acid sequence SEQ ID NO:
- 6.
A recombinant T cell receptor (TCR) that binds to a KRAS G12D neoantigen, comprising a TCR-alpha chain variable region and a TCR-beta chain variable region, wherein
- the TCR-alpha chain variable region comprises:
- a. a CDR1 sequence comprising an amino acid sequence set forth in SEQ ID NOs:
- 19, 29, 39, 49, 59, 69, 79, or 89;
- and
- b. a CDR2 sequence comprising an amino acid sequence set forth in SEQ ID NOs:
- 20, 30, 40, 50, 60, 70, 80, or 90;
- and
- c. a CDR3 sequence comprising an amino acid sequence set forth in SEQ ID NOs:
- 21, 31, 41, 51, 61, 71, 81, or 91;
- and
- the TCR-beta chain variable region comprises:
- d. a CDR1 sequence comprising an amino acid sequence set forth in SEQ ID NOs:
- 16, 26, 36, 46, 56, 66, 76, or 86;
- and
- e. a CDR2 sequence comprising an amino acid sequence set forth in SEQ ID NOs:
- 17, 27, 37, 47, 57, 67, 77, or 87;
- and
- f. a CDR3 sequence comprising an amino acid sequence set forth in SEQ ID NOs:
- 18, 28, 38, 48, 58, 68, 78, or 88.
An engineered cell that expresses a recombinant TCR comprising:
- a TCR-alpha chain comprising a TCR-alpha variable region;
- and
- a TCR-beta chain comprising a TCR-beta variable region;
- wherein the TCR-alpha variable region comprises the following:
- a. a CDR1 comprising the amino acid sequence SEQ ID NO:
- 7,
- b. a CDR2 comprising the amino acid sequence SEQ ID NO:
- 8, and
- c. a CDR3 comprising amino the acid sequence SEQ ID NO:
- 9;
- and
- wherein the TCR-beta variable region comprises the following:
- d. a CDR1 comprising the amino acid sequence SEQ ID NO:
- 3,
- e. a CDR2 comprising the amino acid sequence SEQ ID NO:
- 4, and
- f. a CDR3 comprising the amino acid sequence SEQ ID NO:
- 6;
- and
- wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
- a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
- b. an endogenous T cell receptor beta subunit constant gene (TRBC),
- wherein the at least one heterologous gene comprises at least one of:
- a. a variable region of a heterologous human TCR-a chain gene, and
- b. a variable region of a heterologous human TCR-β chain gene;
- and
- wherein intracellular delivery of the at least one heterologous gene comprises introducing the at least one heterologous gene using a viral vector.
An engineered cell that expresses a recombinant TCR comprising:
- a TCR-alpha chain comprising a TCR-alpha variable region;
- and
- a TCR-beta chain comprising a TCR-beta variable region;
- wherein the TCR-alpha chain variable region comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 10 and the TCR-beta chain variable region comprises at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 11;
- and
- wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
- a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
- b. an endogenous T cell receptor beta subunit constant gene (TRBC),
- wherein the at least one heterologous gene comprises at least one of:
- a. a variable region of a heterologous human TCR-a chain gene, and
- b. a variable region of a heterologous human TCR-β chain gene;
- and
- wherein intracellular delivery of the at least one heterologous gene comprises introducing the at least one heterologous gene using a viral vector.
An engineered cell that expresses a recombinant TCR comprising:
- a TCR-alpha chain comprising a TCR-alpha variable region;
- and
- a TCR-beta chain comprising a TCR-beta variable region;
- wherein the TCR-alpha chain comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 12;
- and
- wherein the TCR-beta chain comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 13, SEQ ID NO:
- 14, or 15;
- and
- wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
- a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
- b. an endogenous T cell receptor beta subunit constant gene (TRBC),
- wherein the at least one heterologous gene comprises at least one of:
- a. a variable region of a heterologous human TCR-a chain gene, and
- b. a variable region of a heterologous human TCR-β chain gene;
- and
- wherein intracellular delivery of the at least one heterologous gene comprises introducing the at least one heterologous gene using a viral vector.
Dependencies are inferred from the claim text.